Champions Oncology Inc (DE:2I3)
FRANKFURT:2I3
2I3 Stock Chart & Stats
€5.50
€0.00(0.00%)
At close: 4:00 PM EST
€5.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.70 - €7.45
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€67.87M
Enterprise Value€78.90M
Total Cash (Recent Filing)€7.13M
Total Debt (Recent Filing)€5.00M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Jul 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding13,886,826
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)25.89
Price to Sales (P/S)1.72
P/FCF Ratio13.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.09
Revenue Forecast (FY)€55.63M
Bulls Say, Bears Say
Bulls Say
Record Services GrowthChampions’ core fee-for-service CRO business showed durable demand: record study revenue grew ~32% YoY driven by strong study execution and backlog conversion. A steady services pipeline and repeatable study workflows support recurring fee revenue and scalable operating leverage over multiple quarters.
Positive Cash Generation & Manageable LeverageDespite profit volatility, TTM operating and free cash flow are positive and the company reported $7.1M cash with no debt this quarter. That cash generation and modest leverage provide runway to fund data investments or tolerate lumpy revenue without immediate financing, improving resilience.
Strategic Shift To Data-driven PlatformAppointment of an experienced data/AI oncology director and explicit investments in sequencing, data commercialization and integrated tumor models signal a structural pivot. Building molecular + clinical datasets can create higher-margin, recurring licensing and analytics revenue over several years.
Bears Say
Top-line DeclineTrailing twelve‑month revenue weakness (~-29%) highlights vulnerability to study timing and data recognitions. Persistent top‑line declines reduce absorption of fixed costs, limit scale benefits, and make multi‑period planning for data platform investments and R&D harder to sustain without steady contract flow.
Margin And Profitability VolatilityGross margin fell sharply (quarter to 47% from 61%) and results swung from profitable FY2025 to TTM losses. This volatility undermines durable margin expectations, raises the risk that operating leverage won’t reliably translate to sustained GAAP profitability, and can force cutbacks or external funding.
Data Revenue & Financing Timing UncertaintyThe nascent data business is lumpy—no data revenue this quarter versus prior-year data recognition—and management gave no firm timetable for external funding of Corellia. Uncertain timing of data deals and subsidiary financing risks delaying expected high-margin revenue and EBITDA upside.
Champions Oncology News
2I3 FAQ
What was Champions Oncology Inc’s price range in the past 12 months?
Champions Oncology Inc lowest stock price was €4.70 and its highest was €7.45 in the past 12 months.
What is Champions Oncology Inc’s market cap?
Champions Oncology Inc’s market cap is €67.87M.
When is Champions Oncology Inc’s upcoming earnings report date?
Champions Oncology Inc’s upcoming earnings report date is Jul 16, 2026 which is in 37 days.
How were Champions Oncology Inc’s earnings last quarter?
Champions Oncology Inc released its earnings results on Mar 12, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of €0.078 by -€0.095.
Is Champions Oncology Inc overvalued?
According to Wall Street analysts Champions Oncology Inc’s price is currently Overvalued.
Does Champions Oncology Inc pay dividends?
Champions Oncology Inc does not currently pay dividends.
What is Champions Oncology Inc’s EPS estimate?
Champions Oncology Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Champions Oncology Inc have?
Champions Oncology Inc has 13,886,826 shares outstanding.
What happened to Champions Oncology Inc’s price movement after its last earnings report?
Champions Oncology Inc reported an EPS of -€0.017 in its last earnings report, missing expectations of €0.078. Following the earnings report the stock price went down -4.472%.
Which hedge fund is a major shareholder of Champions Oncology Inc?
Currently, no hedge funds are holding shares in DE:2I3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Champions Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.37%
12-Months-Change
Fundamentals
Return on Equity
-57.20%
Trailing 12-Months
Asset Growth
-7.12%
Trailing 12-Months
Company Description
Champions Oncology Inc
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
2I3 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid operational execution — record services revenue, ~32% growth in core study revenue, and a third consecutive positive adjusted EBITDA — alongside deliberate investments in data and a therapeutic subsidiary (Corellia). However, near-term challenges include a modest overall revenue decline (~3%) driven by absence of prior-year data license revenue, compression of gross margin (61% to 47%) driven in part by outsourced radiolabeling costs, and elevated operating expenses (~+36%). Data revenue remains early and variable, and Corellia funding timing is uncertain. On balance, the positive operational momentum and pathway to monetize data and Corellia slightly outweigh the near-term margin and timing headwinds.View all DE:2I3 earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---